Zhi Tong Cai Jing·2025-11-18 09:53Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China, indicating progress in the commercialization of this product for chronic constipation treatment [1][1]. Group 1: Company Developments - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]. - As of October 2025, the total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder products, including this drug, is approximately RMB 6.21 million (unaudited) [1]. - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]. Group 2: Market Potential - According to the latest data from IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 873 million in 2024 [1].